Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic (Part 1) and Safety and Tolerability of BI 1015550 on Top of Nintedanib and Pirfenidone (Part 2)
Phase of Trial: Phase I
Latest Information Update: 22 May 2018
At a glance
- Drugs BI 1015550 (Primary) ; Nintedanib; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 20 Mar 2018 Status changed from not yet recruiting to recruiting.
- 05 Mar 2018 Planned initiation date changed from 21 Feb 2018 to 9 Mar 2018.
- 08 Feb 2018 New trial record